Ocuphire Pharma (OCUP) Stock Price, News & Analysis

Company Overview

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.

Key Stats

• Today's Range: N/A
• 50-Day Range: $1.17 to $1.46
• 52-Week Range: N/A
• Volume: 676,700 shs
• Average Volume: 171,840 shs
• Market Capitalization: $30.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.00
• Consensus Rating: Buy

Ocuphire Pharma Stock Analysis - MarketRank™

Ocuphire Pharma scored higher than 21% of companies evaluated by MarketBeat, and ranked 880th out of 955 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Ocuphire Pharma has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Ocuphire Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Ocuphire Pharma are expected to decrease in the coming year, from ($1.11) to ($1.26) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ocuphire Pharma is -2.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ocuphire Pharma is -2.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for OCUP.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ocuphire Pharma does not currently pay a dividend.

Dividend Growth

Ocuphire Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for OCUP.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for OCUP on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Ocuphire Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.70% of the stock of Ocuphire Pharma is held by insiders.

Percentage Held by Institutions

Only 14.97% of the stock of Ocuphire Pharma is held by institutions.

OCUP Stock Analysis - Frequently Asked Questions

How were Ocuphire Pharma's earnings last quarter?

Ocuphire Pharma, Inc. (NASDAQ:OCUP) posted its earnings results on Friday, August, 11th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.01. The firm earned $3.67 million during the quarter. Ocuphire Pharma had a negative net margin of 85.75% and a negative trailing twelve-month return on equity of 30.19%.

What other stocks do shareholders of Ocuphire Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ocuphire Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Arista Networks (ANET), Broadcom (AVGO), ServiceNow (NOW), Novo Nordisk A/S (NVO) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 8/11/2023
• Today: 1/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:OCUP
• CUSIP: N/A
• CIK: 1228627
• Web: www.ocuphire.com
• Phone: (248) 681-9815
• Fax: 240-268-5310
• Employees: 14
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $16.00
• High Stock Price Target: $20.00
• Low Stock Price Target: $10.00
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-9,990,000.00
• Net Margins: -85.75%
• Pretax Margin: -85.68%
• Return on Equity: -30.19%
• Return on Assets: -27.55%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.68
• Quick Ratio: 10.68

Sales & Book Value

• Annual Sales: $16.45 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.20 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 25,924,000
• Free Float: 24,469,000
• Market Cap: $30.33 million
• Optionable: Optionable
• Beta: 0.20